Overview
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
Eligibility
Inclusion Criteria:
- The investigators concluded that the participants continued to benefit from treatment with Jaktinib.
- The participants have been fully informed and voluntarily signed informed consent.
- The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.
- The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.
Exclusion Criteria:
- There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal.
- Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection.
- The investigators considered participants unsuitable for this study.